Granted Patent B2

US 7,947,744 · App. 11/325,875 · Granted May 24, 2011

Abstract

Claims (38)

1. A method of reducing degradation of R,R-formoterol L-tartrate salt in a dry powder inhalation device, said method comprising providing a pharmaceutical product which comprises:

a) a dry powder inhalation device;

b) an effective amount of a sorbent material; and

c) a pharmaceutical composition within said device comprising:

(i) R,R-formoterol L-tartrate salt; and

(ii) ciclesonide;

and sealing components a), b) and c) in a package having an enclosed volume within which said device, said sorbent material and said pharmaceutical composition are situated; wherein a component of said dry powder inhalation device leaches a substance that accumulates within said sealed package causing degradation of said R,R-formoterol L-tartrate salt; wherein said sorbent material is selected from the group consisting of: a molecular sieve, activated clay, charcoal, activated alumina, silica, a zeolite, a bauxite, and a mixture thereof; and wherein said sorbent material adsorbs or absorbs, or a combination thereof, the substance that leaches so as to reduce or eliminate the formation of adducts with R,R-formoterol L-tartrate salt.

2. The method according to claim 1 , wherein said R, R-formoterol L-tartrate salt is crystalline R,R-formoterol L-tartrate salt.

3. The method according to claim 1 , wherein said component of the dry powder inhalation device comprises polyacetal material, and said substance is formaldehyde.

4. The method according to claim 3 , wherein said polyacetal metal is polyoxymethylene.

5. The method according to claim 1 , wherein said sorbent material is housed within said dry powder inhalation device.

6. The method according to claim 1 , wherein said sorbent material is in a porous sachet.

7. The method according to claim 1 , wherein said sorbent material is 10 Å molecular sieves.

8. The method according to claim 1 , wherein said pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

9. The method according to claim 8 , wherein said pharmaceutically acceptable carrier is a reducing sugar.

10. The method according to claim 9 , wherein said reducing sugar is lactose monohydrate.

11. The method according to claim 8 , wherein said pharmaceutical composition comprises about 2969 μg to about 3016 μg of said pharmaceutically acceptable carrier per about 0.5 μg to about 4 μg of R,R-formoterol L-tartrate salt.

12. The method according to claim 8 , wherein said pharmaceutical composition comprises about 2969 μg to about 3016 μg of said pharmaceutically acceptable carrier per about 1 μg to about 2 μg of R,R-formoterol L-tartrate salt.

13. The method according to claim 8 , wherein said pharmaceutical composition comprises about 2969 μg to about 3016 μg of said pharmaceutically acceptable carrier per about 1 μg of R,R-formoterol L-tartrate salt.

14. The method according to claim 9 , wherein said reducing sugar is not micronised.

15. The method according to claim 9 , wherein said reducing sugar has a mean particle size of about 41 μm.

16. The method according to claim 9 , wherein said reducing sugar is selected from the group consisting of lactose, lactose monohydrate, glucose, glucose monohydrate, mannose, galactose, maltose, maltose hydrate, xylose, cellobiose, mellibiose, maltotriose and combinations thereof.

17. The method according to claim 9 , wherein said reducing sugar is lactose.

18. The method according to claim 8 , wherein said pharmaceutically acceptable carrier is non-micronized lactose monohydrate having a particle size of about 41 μm.

19. The method according to claim 1 , wherein said sorbent material is an effective amount of 10 Å sieves enclosed in a porous sachet.

20. The method according to claim 19 , wherein said effective amount of 10 Å sieves is 4 g.

21. The method according to claim 1 , wherein said dry powder inhalation device comprises a multi-dose reservoir that contains said pharmaceutical composition.

22. The method according to claim 1 , wherein said sorbent material is incorporated into a polymer mixture and manufactured into a component of said dry powder inhalation device.

23. The method according to claim 1 , wherein said sorbent material is incorporated into plastic sheeting used in packaging said dry powder inhalation device.

24. The method according to claim 1 , wherein said sorbent material is incorporated into an adhesive.

25. The method according to claim 1 , wherein said R,R-formoterol L-tartrate salt has a particle size of about 0.1 μm to about 10 μm.

26. The method according to claim 1 , wherein greater than about 95% of said R,R-formoterol L-tartrate salt has a particle size of less than about 5 μm.

27. The method according to claim 1 , wherein said sealed package is made of metal, glass, or plastic, and has a configuration selected from the group consisting of a bottle, a bag, a drum box, and an irregularly shaped container.

28. The method according to claim 1 , wherein said sealed package is made of plastic.

29. The method according to claim 1 , wherein said sealed package is a flexible laminate comprising an inner layer, a barrier layer, and an outer layer, wherein said barrier layer is located between said inner layer and said outer layer.

30. The method according to claim 29 , wherein said inner layer is polyethylene, said barrier layer is a metal foil, wherein said metal is selected from the group consisting of aluminum, copper, steel, zinc, tin, magnesium, and an amalgam thereof, and said outer layer comprises polyester or paper.

31. The method according to claim 30 , wherein said flexible laminate comprises a 12 micron polyester outer layer, a 9 micron aluminum foil barrier layer, and a 50 micron polyethylene inner layer.

32. The method according to claim 1 , wherein said sealed package is hermetically sealed using heat-sealing, glue, a weld, brazing said sealed package, a mechanical closure or clamp, or compression of said sealed package.

Assignments (18)